#ROS1

@seldon-dengyue.bsky.social

1 week ago

🧬 5 terapias dirigidas innovadoras de China
🎯 5 mecanismos clave
🌍 1 objetivo: transformar el tratamiento del cáncer de pulmón

#CáncerDePulmón #CPNM #SaludPulmonar #TerapiaDirigida #Biotecnología #EGFR #ALK #ROS1 #Antiangiogénesis #PD1 #VEGF #InnovaciónChina #DengYueMedicinasEnHongKong

0 0 0 0

Bernard A. Fox

@bernardafox.bsky.social

4 months ago

Dr Kailyn FEI from #Chinese #Academy of #Medical #Sciences ( #CAMS )representing #Chinese society #Clinical #Oncology ( #CSCO ) looks at role for chemo #immunotherapy in rare mutant #NSCLC / #BRAF #ROS1 #RET / lots unpublished - not posted - data / #WIC2025 #SITC2025

0 0 0 0

Molecular Oncology

@moloncology.bsky.social

6 months ago

The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients

👉 buff.ly/X1aoIai

#ROS1 #NSCLC #Oncofusions

0 0 0 0

cancergrace

@cancergrace.bsky.social

7 months ago

El Dr. Daniel Rosas presentando: Nuevas Terapias para Tumores ALK y ROS1 e Indicaciones Adjuvantes.

¿Qué son ALK y ROS1?

#Cáncerdepulmón #ALK #ROS1 #TerapiasDirigidas #Mutacionesdecancerdepulmon #pruebasgenéticas

1 0 0 0

OncoDaily

@oncodaily.bsky.social

9 months ago

FDA Approves Taletrectinib for ROS1-Positive NSCLC Treatment FDA approves taletrectinib for ROS1-positive NSCLC. TRUST-I/II trials show high systemic & intracranial responses in advanced NSCLC.

FDA approval of Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer
@fda.gov

oncodaily.com/opinion/311850

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer #FDA #Taletrectinib #ROS1

6 1 0 0

Gautam Salhotra

@gautamsalhotra.com

9 months ago

Mark ROS Noetic as end-of-life by sloretz · Pull Request #46184 · ros/rosdistro Do not merge until May 31st https://discourse.ros.org/t/ros-noetic-end-of-life-may-31-2025/43160 #46038

TIL #ROS1 reached end-of-life. ROS didn't just teach me robotics; it made robotics accessible for all. Bringing robotic ideas to life felt so much easier. While official ROS support ends, its impact on practitioners like me is eternal.
🫡 @openrobotics.bsky.social
github.com/ros/rosdistr...

0 0 0 0

cancergrace

@cancergrace.bsky.social

1 year ago

Dr. @ChristineBestv1 now presenting: ALK, ROS1 and RET: Pushing the Boundaries of Targeted Therapies

#ALK #ROS1 #RET #LungCancer #TargetedTherapies #cancerGRACE

8 6 1 0

cancergrace

@cancergrace.bsky.social

1 year ago

Dr. Karen Yun presenting: How Do You Read a Molecular Testing Report?

What are Driver Alterations in Lung Cancer?

#TargetedTherapiesInLungCancer #LungCancer #ALK #ROS1 #RET #NTRK #EGFR #BRAF #MET #HER2 #KRAS

7 4 0 1

cancergrace

@cancergrace.bsky.social

1 year ago

Now Dr. Jennifer Marks presenting Biomarker Testing 101 for Lung Cancer at our Targeted Therapies in Lung Cancer.

What is a #biomarker?

#ALk #ROS1 #LungCancer #TargetedTherapies #cancerGRACE #CancerEducation

2 1 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago

Analyzing ROZLYTREK's Market Dynamics and Competition in Treating Cancers Explore the growth of ROZLYTREK in targeting NTRK and ROS1-positive cancers, its market dynamics, and the competitive landscape ahead.

Analyzing ROZLYTREK's Market Dynamics and Competition in Treating Cancers #None #ROZLYTREK #NTRK #ROS1

0 0 0 0

Hidehito HORINOUCHI

@hhorinouchi.bsky.social

1 year ago

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study PURPOSEDatopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II tr...

🔥Journal of Clinical Oncology🆙
✅TROPION-Lung05: Dato-DXd in Advanced or Metastatic NSCLC With Actionable Genomic Alterations
🎯 #EGFR #ALK #ROS1 #RET #BRAF #MET
👥Dr. Jacob Sands
✅NCT04484142
#LCSM @oncoalert.bsky.social @ascocancer.bsky.social @ascopost.bsky.social
ascopubs.org/doi/10.1200/...